Statins as Repurposed Drugs in Gynecological Cancer: A Review

Kai-Hung Wang 1, Chin-Hung Liu 2 and Dah-Ching Ding 3,4,*

1 Department of Medical Research, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien 970, Taiwan
2 Department of Pharmacology, School of Medicine, Tzu Chi University, Hualien 970, Taiwan
3 Department of Obstetrics and Gynecology, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Foundation, and Tzu Chi University, Hualien 970, Taiwan
4 Institute of Medical Sciences, College of Medicine, Tzu Chi University, Hualien 970, Taiwan
* Correspondence: dah1003@tzuchi.com.tw; Tel.: +886-38561825-13381

Abstract: Discovering new drugs is an expensive and time-consuming process, including target identification, bioavailability, pharmacokinetic (PK) tests, pharmacodynamic (PD) tests, toxicity profiles, recommended dosage test, and observation of the side effects, etc. Repurposed drugs could bypass some steps, starting from phase II trials, and shorten the processes. Statins, also known as HMG-CoA inhibitors (HMGCR), are commonly used to manage and prevent various cardiovascular diseases and have been shown to improve the morbidity and mortality of patients. In addition to the inhibitory effects on the production of cholesterol, the beneficial effects of statins on the prognosis and risk of various cancers are also shown. Statins not only inhibited cell proliferation, metastasis, and chemoresistance but affected the tumor microenvironment (TME). Thus, statins have great potential to be repurposed in oncology. Hence, we review the meta-analysis, cohort, and case-control studies of statins in gynecological cancers, and elucidate how statins regulate cell proliferation, apoptosis, tumor growth, and metastasis. Although the results in gynecological cancers remain controversial and the effects of different statins in different histotypes of gynecological cancers and TME are needed to elucidate further, statins are excellent candidates and worthy of being repurposed drugs in treating gynecological cancers.

Keywords: statins; repurposed drugs; gynecological cancer; endometrial cancer; ovarian cancer; cervical cancer

1. Introduction

Gynecological cancer is any cancer that starts in a woman’s reproductive organs, including cervical, endometrial, ovarian, vaginal, and vulvar cancer. The treatments generally include surgery, radiation therapy, chemotherapy, target therapy, and immunotherapy. Combination therapy is a trend worldwide. However, discovering new drugs or targets is always the mission against cancers. There is an established setting for new drug discovery from pre-clinical results, in vitro and in vivo, to human studies, phase I and II trials, and a phase III randomized controlled trial (RCT). It is expensive and takes over 10 years in all processes [1]. Thus, if the existing drugs could be repurposed, it can dramatically reduce costs and save time, benefiting patients who suffer from these malignant and lethal diseases.

Statins, as 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase competitive inhibitors (HMGCR), are commonly used as lipid-lowering drugs, preventing cardiovascular diseases. However, the anti-cancer properties of statins have been investigated in recent decades, showing better prognoses in various types of cancer through various mechanisms [2,3]. The evidence of the anti-cancer effects of statins in gynecological cancers is sparse and controversial, thus, we review and assess the potential of statins as repurposed drugs in treating gynecological cancers.
2. Cervical Cancer and Human Papillomavirus (HPV)

Cervical cancer is the fourth most common cancer in women and the fourth highest mortality rate worldwide. Cervical cancer diagnoses for 6.6% of all cancer types with a mortality rate of 7.5% in 2018 [4]. For diagnosis of cervical cancer from cytologic examination, the precancerous stage includes low-grade squamous intra-epithelial lesion (LSIL or mild dysplasia) and high-grade squamous intra-epithelial lesion [HSIL or moderate dysplasia, severe dysplasia, and carcinoma in situ (CIS)], and the cancer types include squamous cell carcinoma (SCC), and adenocarcinoma. The diagnosis of cervical cancer from histologic examination includes cervical intraepithelial neoplasia 1 (CIN1), CIN2, and CIN3 and cancer lesions. LSIL is relatively equal to CIN1, while HSIL is relatively equal to CIN2 and CIN3 [5].

Human papillomavirus (HPV) has been defined as a carcinogen, especially the high-risk types, and the persistence of HPV infection was a necessary etiological cause of cervical cancer [6]. High-risk HPV (HR-HPV) types include HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 [7]. Inoculation of HPV vaccines showed long-term efficacy and could prevent cervical cancer [8]. The ideal age for the administration of the HPV vaccines is 10 to 13 years. In low-resource settings, the simple and inexpensive way is to start with visual inspections only or in combination with HPV tests. In high-resource situations, it starts with cytologic tests (pap smear test) and HPV tests to screen cervical cancer patients [9].

3. Endometrial Cancer and Its Risk Factors

Endometrial cancer (EC) is the sixth most common cancer in females and the second most commonly diagnosed cancer of female reproductive organs. Around 417,000 new cases were detected, and 97,000 women died worldwide from the disease in 2020 [10] [11]. There are two main types of ECs that were characterized. Type I ECs, around ~80%, are mostly well differentiated with endometrioid histology and show a high level of estrogen receptor (ER). Type II ECs are poorly differentiated with serous or clear cell histology and show a high recurrence rate (80%–90%) within 3 years, representing a poor prognosis [12]. In addition, ECs can be low-grade (grades 1 and 2) tumors which are generally associated with a better prognosis, or high-grade carcinomas (grade 3) carrying an intermediate prognosis [13]. The risk factors for EC include high body mass index (BMI: kg/m^2), often with other components of metabolic syndrome (e.g., hypertension, diabetes), nulliparity or infertility, early menarche, and late menopause.

The relative risk (RR) for developing EC with metabolic syndrome was 1.89 [95% confidence interval (CI) 1.34 to 2.67, \( p < 0.001 \)] among the components of metabolic syndrome. Obesity (BMI > 30) was associated with the greatest increase in RR of 2.21 (\( p < 0.001 \)). Other components of the metabolic syndrome linked to endometrial cancer include hypertension, with a RR of 1.81 (\( p < 0.05 \)). [14] Type II Diabetes mellitus (DM) showed an independent risk factor for EC, with an approximate doubling of risk [Odds ratio (OR) was 2.18, 95% CI 1.40 to 3.41] [15]. Among the causes of infertility, polycystic ovarian syndrome (PCOS) showed an increase in risk (OR = 2.79, 95% CI 1.31 to 5.95) [16]. Both early menarche (RR was 2.4 for women <12 vs. \( \geq 15 \) years) [17], and late menopause (RR = 1.8 for women \( \geq 55 \) versus <50 years) [18] are associated with increased risk for EC.

4. Ovarian Cancer and Its Risk Factors

Ovarian cancer is the leading disease of death in females diagnosed with gynecological cancers. In the meantime, it is women’s fifth most frequent cause of death. There are approximately 21,750 new ovarian cancer cases in the US, comprising 1.2% of all cancer cases. The estimated number of deaths related to ovarian cancer was 13,940 in 2020 [19]. Among the ovarian cancer subtypes, type II high-grade serous carcinoma (HGSC) is the most prevalent and lethal, representing more than 70% of ovarian cancer. Type I tumor includes low-grade serous, endometrioid, clear-cell, and mucinous carcinomas, presenting at an early stage and carrying a good prognosis except for clear-cell [20]. HGSCs arise
from serous tubal intraepithelial carcinoma (STIC) in the fimbriae of the tube, undergoing
malignant transformation and metastasizing to the nearby ovaries and peritoneum [21,22].

The risks of ovarian cancer were increasing in postmenopausal women and those with
a family history of breast or ovarian cancer. At the same time, pregnancy, lactation, and oral
contraceptive pills reduced the risks [23]. Moreover, obesity was an independent prognostic
factor in addition to advanced tumor staging and positive ascites cytology. The hazard
ratio (HR) of overall survival (OS) was 1.871, 95% CI 1.005 to 3.486 in all ovarian cancer
patients, and the HR was elevated to 2.405, 95% CI 1.335 to 4.333 in pT3 stage patients [24].

5. Statins, HMG-CoA Reductase Inhibitor (HMGCR) and the Role in the Tumor
Microenvironment (TME)

5.1. Statins, Lipid-Lowering Drugs

Statins are traditionally applied in cardiovascular diseases to reduce cholesterol [25]
and could be divided into two groups: type-I derivatives (from fermentation, includ-
ing mevastatin, lovastatin, pravastatin, and simvastatin), and type-II drugs (from the
synthetic origin, including fluvastatin, atorvastatin, cerivastatin, pitavastatin, and rosuvas-
tatin) [26,27]. The main role of statin in the mevalonate pathway is inhibiting HMG-CoA
reductase (HMGCR), resulting in the depletion of LDL cholesterol [28] (Figure 1). The
statins were used between 10–80 mg, and the metabolic pathway of statins was major
through CYP3A4 [29] (Table 1). However, recent studies suggested that statins could have
anti-tumor effects (Figures 1 and 2), from meta-analysis and bench, in vitro and in vivo.

![Figure 1](https://example.com/figure1.png)

**Figure 1.** The mevalonate pathway and the role of statin in regulating tumor progression and
biosynthesis of cholesterol.

| Drugs      | Property     | High Dose  | Moderate Dose | Low Dose  | Metabolism Pathway |
|------------|--------------|------------|---------------|-----------|--------------------|
| Atorvastatin | lipophilic   | 40–80 mg   | 10–20 mg     |           | CYP3A4             |
| Fluvastatin | lipophilic   | 80 mg      | 20–40 mg     |           | CYP2C9             |
| Lovastatin  | lipophilic   | 40 mg      | 20 mg        |           | CYP3A4             |
| Pravastatin | hydrophilic  | 40–80 mg   | 10–20 mg     |           | Sulfation          |
| Rosuvastatin| hydrophilic  | 20–40 mg   | 5–10 mg      |           | CYP2C9             |
| Simvastatin | lipophilic   | 20–40 mg   | 10 mg        |           | CYP3A4             |

CYP3A4: cytochrome P450, subfamily IIIA, polypeptide 4. CYP2C9: cytochrome P450, subfamily IIC, polypeptide
CYP3A4: cytochrome P450, subfamily IIIA, polypeptide 4. CYP2C9: cytochrome P450, subfamily IIC, polypeptide

9. High dose: reduce LDL ≥ 50%, moderate dose: reduce LDL 30–49%, low dose: reduce LDL < 30%.
5.2. Statins in Cancer

The most investigated statin in cancer is simvastatin. In general, the role of statins was tumor suppressor. Statins could induce cancer cell apoptosis through traditional caspases cascade and inhibit cell proliferation, migration, invasion, epithelial-mesenchymal transition (EMT), and chemoresistances in various types of cancer (Figure 2), including breast, lung, pancreas, and liver cancer [30]. Statins induced apoptosis of cancer cells through NFκB and the canonical caspase pathway and reduced proliferation through MEK1/2, ERK1/2, and JNK pathways [31]. Statins also induced cell cycle arrest of cancer cells by activating AMPK and increasing p21 and p27 expression [32]. Simvastatin suppresses the invasion of cancer cells by decreasing Pituitary Tumor-Transforming Gene 1 (PTTG1) [33]. Furthermore, statins could also regulate epigenetic machinery resulting in cell cycle arrest. DNMTs could be the targets of statins and the downstream p16 protein [34] and p21 [35]. In conclusion, statins showed anti-tumor progression in various cancers (Figure 2).

5.3. Statins in Immune Cells

Mostly, statins showed anti-inflammatory effects and enhanced the number of regulatory T cells (Treg) [36], which may result in the suppression of the Th1 immune response [37]. In addition, statin treatment reduced the Th17 population [38]. Treg obtained immunosuppressive effects on immunotherapy. However, a high dose of Atorvastatin could reduce the in vitro function of conventional T and regulatory T (Treg) cells [39]. Furthermore, statins were associated with better clinical outcomes in patients treated with PD-1 inhibitors [40]. Statins plus Th1 cytokines or dendritic cells (DC)-based immunotherapy could suppress breast tumor growth [41]. Statins could stimulate immunogenicity and promote an anti-melanoma immune response [42]. These data showed the conflicting roles of statins in immunotherapy. Thus, the roles of statins in immune cells and immunotherapy are needed to be elucidated.

5.4. Statins in MSCs

Statins had several effects on mesenchymal stem cells (MSCs). Statins could enhance the osteogenic differentiation, angiogenic potential, migration, homing, survival, and

Figure 2. The effects of statins on anti-tumor progression and tumor microenvironment (TME). TME includes immune cells and MSCs. Green arrows represent inhibitory effects, and red arrows represent promoting effects.
proliferation of MSCs [43], which may have improved therapeutic outcomes in regenerative medicine. The evidence of statins in regulating cancer-associated MSCs (CaMSCs) is limited. Simvastatin could decrease CCL3 expression from cancer cells and ICAM-1, VCAM1, IL-6, and CCL2 expression from CaMSCs, disrupting the crosstalk of the cancer cells and tumor microenvironments (TME) and inhibiting tumor progression [44]. Therefore, the roles of statins in the TME—not only in immune cells but also MSCs, especially CaMSCs—need further investigation.

6. Statins as Potential Anti-Cancer Agents in Gynecological Cancers

6.1. Meta-Analysis in EC

Statin use was associated with lower risks of EC (RR = 0.81, 95% CI 0.70 to 0.94, \( p = 0.001 \)) but not with mortalities (HR = 0.71, 95% CI 0.64 to 0.80, \( p = 0.144 \)) [45]. In another study, it was shown that statin use could increase overall survival (OS) (HR = 0.80, 95% CI 0.66 to 0.95) [46]. However, not all studies suggested positive results. It was shown that statin use did not reduce the risk of EC (RR = 0.88, 95% CI 0.78 to 1.00, \( p = 0.05 \)), even in the long-term statin user (>5 years) (RR = 0.79, 95% CI 0.58 to 1.08, \( p = 0.14 \)) [47]. There was also no protective effect on EC in another study (RR = 0.94, 95% CI 0.82 to 1.07) [48] (Table 2).

Table 2. Clinical studies of statins in endometrial cancer.

| Study Type      | Findings in Statin Use Group                          | Results                                                   | References |
|-----------------|-------------------------------------------------------|-----------------------------------------------------------|------------|
| Meta-analysis   | Decrease risks and mortality of endometrial cancer.   | Risk: RR = 0.81, 95% CI 0.70 to 0.94; OS: HR = 0.71, 95% CI 0.64 to 0.80. | [45]       |
| Meta-analysis   | Decrease mortality of endometrial cancer.              | Mortality: HR = 0.80, 95% CI 0.66 to 0.95.                | [46]       |
| Meta-analysis   | No protective effect on endometrial cancer.            | Risk: RR = 0.88, 95% CI 0.78 to 1.00; long-term use (>5 years) RR = 0.79, 95% CI 0.58 to 1.08. | [47]       |
| Meta-analysis   | No protective effect on endometrial cancer.            | Risk: RR = 0.94, 95% CI 0.82 to 1.07.                     | [48]       |
| Cohort study    | No protective effect on endometrial cancer.            | HR = 0.67, 95% CI: 0.39 to 1.17.                          | [49]       |
| Cohort study    | No protective effect on survival in endometrial cancer. | Mortality: Type I HR 0.92, 95% CI 0.70 to 1.2; type II HR = 0.92, 95% CI 0.65 to 1.29. | [50]       |
| Cohort study    | No protective effect on endometrial cancer.            | Risk: HR = 0.83, 95% CI 0.64 to 1.08.                     | [51]       |
| Cohort study    | No protective effect on endometrial cancer.            | Recurrence-free survival (82% vs. 83%); disease-specific survival (86% vs. 84%); and OS (77% vs. 75%). | [52]       |
| Cohort study    | Decrease mortality of endometrial cancer.              | Mortality: HR = 0.41, 95% CI 0.20 to 0.82.                | [53]       |
| Cohort study    | Decrease mortality of endometrial cancer.              | Mortality: HR = 0.80, 95% CI, 0.74 to 0.88.               | [3]        |
| Cohort study    | Improve DSS of endometrial cancer, especially concurrent use with aspirin. | DSS: HR 0.63, 95% CI 0.40 to 0.99; concurrent use with aspirin HR 0.25, 95% CI 0.09 to 0.70. | [54]       |
| Cohort study    | Improve OS and PFS of hyperlipidaemic high-grade endometrial cancer. | Mortality: HR = 0.42, 95% CI, 0.20 to 0.87; PFS: HR = 0.47, 95% CI 0.23 to 0.95. | [55]       |
| Cohort study    | Decrease mortality of endometrial cancer.              | Mortality: continuing user HR = 0.70, 95% CI 0.53 to 0.92; new users HR = 0.43, 95% CI 0.29 to 0.65. | [56]       |
| Cohort study    | Decrease mortality of type I endometrial cancer and statin new user. | Mortality: type I HR = 0.87, 95% CI 0.76 to 1.00; hydrophilic statins HR = 0.84, 95% CI 0.68 to 1.03; new user HR = 0.75, 95% CI 0.59 to 0.95. | [57]       |
| Cohort study    | Decrease risks of endometrial cancer.                  | Risk: HR = 0.74, 95% CI 0.59 to 0.94.                      | [58]       |

CI: confidence interval. RR: relative risk. OR: odds ratio. OS: overall survival. HR: hazard ratio. DSS: disease-specific survival. PFS: progression-free survival.
6.2. Cohort Studies in EC

The results of statins use in EC are controversial, including no protective effects on risks (HR = 0.67, 95% CI: 0.39–1.17) [49], OS for type I (HR = 0.92, 95% CI 0.70 to 1.2) and type II (HR = 0.92, 95% CI 0.65 to 1.29, \( p = 0.62 \)) EC patients [50]. There was no significant association in post-diagnostic use of statins (new users) (adjusted HR 0.83, 95% CI 0.64 to 1.08) [51] and no difference between statin users and nonusers in 5-year recurrence-free survival (82% vs. 83%; \( p = 0.508 \)), disease-specific survival (86% vs. 84%; \( p = 0.549 \)), or overall survival (77% vs. 75%; \( p = 0.901 \)) [52] (Table 2).

In contrast, statin use decreased the mortalities in several studies, including OS (HR = 0.41, 95% CI 0.20 to 0.82) [53], OS (HR = 0.80, 95% CI 0.74–0.88) [3], disease-specific survival (DSS) (HR = 0.63, 95% CI 0.40 to 0.99), DSS in concurrent statin and aspirin user (HR = 0.25, 95% CI 0.09 to 0.70) [54], OS in hyperlipidemic patients (HR = 0.42; 95% CI 0.20 to 0.87; \( p = 0.02 \)), PFS (HR = 0.47; 95% CI 0.23 to 0.95; \( p = 0.04 \)) [55], OS in continuing (pre- and postdiagnosis) users (HR = 0.70, 95% CI 0.53 to 0.92), new (postdiagnosis only) users (HR = 0.43, 95% CI 0.29 to 0.65) [56]. Furthermore, statin use decreased EC-specific mortality in type I cancers (HR = 0.87; 95% CI 0.76 to 1.00), for hydrophilic statins (HR = 0.84; 95% CI 0.68 to 1.03) and the new user (HR = 0.75; 95% CI 0.59 to 0.95) [57]. In addition, the risk of EC for statin use was decreased (HR = 0.74, 95% CI 0.59 to 0.94) [58] (Table 2).

In summary, the effects of statins in treating EC are still controversial. However, large results suggested that statins may be potent drugs to decrease the risks and mortalities of EC, and are worth performing clinical trials.

7. Meta-Analysis in Ovarian Cancer

Statin use was not significantly associated with the risks (RR = 0.92, 95% CI 0.85 to 1.00) but decreased the mortality (HR = 0.78, 95% CI 0.73 to 0.83) of ovarian cancer [45]. Another study showed that statin use did not reduce the risk of ovarian cancer (RR = 0.88, 95% CI 0.76 to 1.03, \( p = 0.12 \)). Furthermore, no association was found between long-term statin use (>5 years) and the risk of ovarian cancer (RR = 0.73, 95% CI 0.51 to 1.04, \( p = 0.08 \)) [47]. It was shown that the risks were not significantly associated with statin type (lipophilic RR = 0.88, 95% CI 0.69 to 1.12; hydrophilic RR = 1.06, 95% CI 0.72 to 1.57), histotypes of ovarian cancer (serous: RR: 0.95, 95% CI 0.69 to 1.30; clear cells: RR = 1.17, 95% CI 0.74 to 1.86), and long-term user (RR = 0.77, 95% CI 0.54 to 1.10) [59] (Table 2).

In summary, the effects of statins in treating EC are still controversial. However, large results suggested that statins may be potent drugs to decrease the risks and mortalities of EC, and are worth performing clinical trials.

| Study Type | Findings in Statin Use Group | Results | References |
|------------|-----------------------------|---------|------------|
| Meta-analysis | No association with risks but decreased mortality of ovarian cancer. | Risk: RR = 0.92, 95% CI 0.85 to 1.00; OS: HR = 0.78, 95% CI 0.73 to 0.83. | [45] |
| Meta-analysis | No protective effect on ovarian cancer. | Risk: RR = 0.88, 95% CI 0.76 to 1.03; long-term use (>5 years) RR = 0.73, 95% CI 0.51 to 1.04. | [47] |
| Meta-analysis | No protective effect on ovarian cancer, regardless of the statin type, tumor histotypes: serous and clear cells, and long-term user. | Risk: lipophilic RR = 0.88, 95% CI 0.69 to 1.12; hydrophilic RR = 1.06, 95% CI 0.72 to 1.57; histotypes of cancer (serous: RR = 0.95, 95% CI 0.69 to 1.30; clear cells: RR = 1.17, 95% CI 0.74 to 1.86), and long-term user (RR = 0.77, 95% CI 0.54 to 1.10). | [59] |
| Meta-analysis | No association with risks but decreased mortality in ovarian cancer. | Risk: RR = 0.88, 95% CI 0.75 to 1.03; OS: RR = 0.76, 95% CI 0.67 to 0.86. | [60] |
| Meta-analysis | Decrease risks of ovarian cancer, especially in long-term use group. | Risk: RR = 0.79, 95% CI 0.64 to 0.98; long-term use (>5 years) RR = 0.48, 95% CI 0.28 to 0.80. | [61] |
| Meta-analysis | Improve OS and decrease cancer-specific mortality in ovarian cancer. | Mortality: HR = 0.74, 95% CI 0.63 to 0.87; cancer-specific mortality (HR = 0.87, 95% CI 0.80 to 0.95. | [62] |
Table 3. Cont.

| Study Type          | Findings in Statin Use Group                                                                 | Results                                      | References |
|---------------------|-------------------------------------------------------------------------------------------------|----------------------------------------------|------------|
| Meta-analysis       | Decrease mortality of ovarian cancer.                                                          | Mortality: HR = 0.76, 95% CI: 0.68–0.85.     | [63]       |
| Meta-analysis       | * Decrease ovarian cancer risks in genetically proxied HMG-CoA reductase inhibition population as well as in BRCA1/2 carrier. | Risk: OR = 0.60, 95% CI 0.43 to 0.83; BRCA1/2 carrier HR = 0.69, 95% CI 0.51 to 0.93. | [64]       |
| Cohort study        | No protective effect on ovarian cancer.                                                        | Risks: HR = 0.69, 95% CI 0.32–1.49.          | [49]       |
| Case-control study  | No protective effect on ovarian cancer.                                                        | Risks: OR = 0.98, 95% CI 0.87 to 1.10.       | [65]       |
| Case-control study  | No protective effect on ovarian cancer.                                                        | Risks: HR = 0.99, 95% CI 0.78 to 1.25.       | [66]       |
| Cohort study        | Increase the risk of ovarian cancer, especially in pravastatin user.                          | Risks: HR = 1.30, 95% CI 1.04 to 1.62; pravastatin HR = 1.89, 95% CI 1.24 to 2.88. | [58]       |
| Cohort study        | No protective effect on ovarian cancer.                                                        | Mortality: HR = 0.57, 95% CI 0.21–1.51.      | [67]       |
| Cohort study        | No protective effect on ovarian cancer.                                                        | Mortality: HR = 0.90, 95% CI 0.78 to 1.04.   | [68]       |
| Cohort study        | No protective effect on ovarian cancer, neither in lipophilic nor hydrophilic statins.          | Mortality: HR = 0.90, 95% CI 0.70 to 1.15; lipophilic statins HR = 0.82, 95% CI 0.61 to 1.11; hydrophilic statins HR = 1.04, 95% CI 0.72 to 1.49. | [69]       |
| Cohort study        | No protective effect on ovarian cancer with hyperlipidemia, but the mortality was decreased in non-serous-papillary subtypes. | Mortality: hyperlipidemia HR = 0.80, 95% CI 0.50 to 1.29; non-serous-papillary subtypes HR = 0.23, 95% CI 0.05 to 0.96. | [70]       |
| Cohort study        | Decrease mortality of ovarian cancer.                                                          | Mortality: HR = 0.45, 95% CI 0.23 to 0.88.   | [71]       |
| Cohort study        | Decrease mortality of ovarian cancer.                                                          | Mortality: HR = 0.47, 95% CI 0.26 to 0.85.   | [72]       |
| Cohort study        | Decrease mortality of ovarian cancer.                                                          | Mortality: HR = 0.81, 95% CI 0.72 to 0.90.   | [73]       |
| Cohort study        | Decrease mortality of ovarian cancer.                                                          | Mortality: HR = 0.74, 95% CI 0.61 to 0.91.   | [74]       |
| Cohort study        | Decreases ovarian cancer mortality, both in serous and non-serous types.                       | Mortality: HR = 0.66, 95% CI 0.53 to 0.81; serous type HR = 0.69, 95% CI 0.54 to 0.87; non-serous type HR = 0.63, 95% CI 0.44 to 0.90. | [75]       |
| Cohort study        | Decrease mortality in all patients and in those who were serous type.                         | Mortality: HR = 0.76, 95% CI 0.64 to 0.89; serous type HR = 0.80, 95% CI 0.67 to 0.96. | [76]       |

* Genetically proxied HMG-CoA reductase inhibition population contained single nucleotide polymorphism (SNP). CI: confidence interval. RR: relative risk. OS: overall survival. HR: hazard ratio.

Similar to previous studies, statin use was not associated with the risk (RR = 0.88, 95% CI 0.75 to 1.03) but could significantly decrease mortality (RR = 0.76, 95% CI 0.67 to 0.86) of ovarian cancer [60]. Another study showed that statin use decreased the risks (RR = 0.79, 95% CI, 0.64 to 0.98) of ovarian cancer, especially in long-term users (>5 years) (RR = 0.48, 95% CI 0.28 to 0.80) [61]. Post-diagnostic statin use could decrease OS (HR = 0.74, 95% CI 0.63 to 0.87) and cancer-specific mortality (HR = 0.87, 95% CI 0.80 to 0.95) [62]. This could be seen in another study, showing improved OS in statin users (HR: 0.76, 95% CI: 0.68–0.85) [63]. Intriguingly, genetically proxied HMG-CoA reductase inhibition equivalent to 1-mmol/L (38.7-mg/dL) reduction in LDL cholesterol, significantly decreased the risk of ovarian cancer (OR = 0.60, 95% CI 0.43 to 0.83) as well as in BRCA1/2 mutation carriers, (HR = 0.69, 95% CI 0.51 to 0.93). [64] (Table 3).

Cohort Studies and Case-Control Studies in Ovarian Cancer

There was no association between the risk of ovarian cancer and statin user, HR = 0.69, 95% CI 0.32–1.49 [49], OR = 0.98, 95% CI 0.87 to 1.10 [65], and HR = 0.99, 95% CI 0.78 to 1.25 [66]. Moreover, the risk was even higher (HR = 1.30, 95% CI 1.04–1.62), which was largely attributed to the effect of the hydrophilic statin, especially pravastatin (HR = 1.89, 95% CI 1.24–2.88) [58]. Statin use was not associated with mortalities of ovarian cancer, HR = 0.57, 95% CI 0.21–1.51 [67], HR = 0.90, 95% CI 0.78 to 1.04 [68], and HR = 0.90, 95% CI 0.70 to 1.15, including lipophilic statin use (HR = 0.82, 95% CI 0.61 to 1.11) and hydrophilic statins (HR = 1.04, 95% CI 0.72 to 1.49) [69], and even in the patients with hyperlipidemia...
(HR = 0.80, 95% CI 0.50 to 1.29) [70]. However, the mortalities were significantly decreased in non-serous-papillary subtypes (HR = 0.23, 95% CI 0.05 to 0.96) [70] (Table 3).

On the contrary, statin use decreased the mortalities of ovarian cancer, HR = 0.45, 95% CI 0.23 to 0.88 [71], HR = 0.47, 95% CI 0.26 to 0.85 [72], HR = 0.81, 95% CI 0.72 to 0.90 [73], HR = 0.74, 95% CI 0.61 to 0.91 [74], and HR = 0.66, 95% CI 0.55 to 0.81 [75], both in serous (HR = 0.69, 95% CI 0.54 to 0.87) and non-serous (HR = 0.63, 95% CI 0.44 to 0.90) histologies [75]. It was also shown that statin use decreased mortality in another study, HR = 0.76, 95% CI 0.64 to 0.89 for all patients and HR = 0.80, 95% CI 0.67 to 0.96 for patients with serous types [76] (Table 3).

Because ovarian cancer has different histotypes, statin use did not show significant differences in risks in serous and clear cell types [59], but the mortality decreased [75,76]. The results of statin use in ovarian cancer patients remained controversial. Thus, additional studies are needed to elucidate the effects of different statins on different histotypes of ovarian cancer.

8. Cohort Studies in Other Gynecological Cancers

The HR association between the risk of cervical cancer and statin use was 0.83, 95% CI of 0.67 to 0.99. Statin use was associated with decreased total gynecological cancer mortality, (HR = 0.70, 95% CI 0.50 to 0.98) [77]. The statin use group had a better prognosis compared with the non-user (progression-free survival: HR = 0.062, 95% CI 0.008 to 0.517; overall survival: HR = 0.098, 95% CI 0.041–0.459) in cervical cancer patients [78] (Table 4). The effects of statin use against cervical cancer and vulvar cancer are not conclusive due to too few studies and case numbers [61]. In conclusion, statin use may obtain protective effects on cervical cancer, but the evidence is too few.

Table 4. Clinical studies of statins in other gynecological cancer.

| Study Type      | Findings in Statin Use Group                                      | Results                                                                 | References |
|-----------------|-------------------------------------------------------------------|-------------------------------------------------------------------------|------------|
| Cohort study    | Decrease risks of cervical cancer; decrease mortality in total   | Risk: HR = 0.83 (95% CI 0.67 to 0.99); total gynecological cancer       | [77]       |
|                 | gynecological cancer.                                              | HR = 0.70, 95% CI 0.50 to 0.98.                                          |            |
|                 |                                                                   |                                                                         |            |
| Cohort study    | Decrease mortality of cervical cancer                              | Progression-free survival: HR = 0.062, 95% CI 0.008 to 0.517; overall   | [78]       |
|                 |                                                                   | survival: HR = 0.098, 95% CI 0.041–0.459.                                |            |

CI: confidence interval. HR: hazard ratio.

9. The Mechanisms of the Anti-Tumor Effects of Statins on Gynecological Cancer

Simvastatin exhibits anti-metastatic and anti-tumorigenic effects in ECC-1 and Ishikawa EC cells through mitogen-activated protein kinase (MAPK) but not the Akt/mTOR pathway [79]. The drug for diabetes, metformin, combined with simvastatin, synergistically inhibited cell growth and induced Bim expression and apoptosis in RL95-2, HEC1B, and Ishikawa EC cells. The combination treatment of metformin and simvastatin upregulated phosphorylated AMPK (pAMPK) and downregulated downstream phosphorylated S6 (pS6), suggesting the mTOR pathway may regulate these anti-proliferative effects [80]. Lipophilic (lovastatin and simvastatin) but not hydrophilic (pravastatin) statins induced apoptosis in ovarian cancer cell lines A2780 and UCI 101; endometrial cancer cell line, Ishikawa; and cervical cancer cell line, HeLa, which all expressed high levels of HMG-CoA reductase [81] (Table 5).
Table 5. The preclinical studies of statin in gynecological cancers.

| Treatment                | Experiments                      | Cell Lines            | Effects of Statins                        | Pathway/Mechanism                  | References |
|--------------------------|----------------------------------|-----------------------|-------------------------------------------|------------------------------------|------------|
| Simvastatin              | in vitro                         | ECC-1 and Ishikawa    | Anti-proliferative and anti-metastatic effects. | MAPK pathway.                      | [79]       |
| Simvastatin + metformin   | in vitro                         | RL95-2, HEC-1B, and Ishikawa | Induce apoptosis; synergized with metformin. | Bim, AMPK/S6.                      | [80]       |
| Lovastatin and simvastatin | in vitro                         | A2780, UCI 101, Ishikawa, and HeLa | Induce apoptosis. | Bim, AMPK/S6.                      | [81]       |
| Lovastatin and Pravastatin | in vitro and in vivo              | SKOV3                 | Anti-metastatic effects, reduce peritoneal dissemination. | Bim, AMPK/S6.                      | [82]       |
| Lovastatin and atorvastatin | in vitro                         | Hey 1B and Ovcar-3    | Induce apoptosis.                         | JNK/Rac1/Cdc42.                    | [83]       |
| Lovastatin + doxorubicin  | in vitro                         | SKOV3 and OVCAR5, mogp-TAg mice | Induced apoptosis; synergized with doxorubicin. |                      | [84]       |
| Lovastatin               | in vitro and in vivo              | RMG-1 and TOV-21G     | Induce apoptosis and anti-tumor growth.    | Osteopontin (OPN).                 | [85]       |
| Simvastatin, atorvastatin, rosuvastatin, lovastatin, fluvasatin, pravastatin | in vitro                         | A2780, Igrov-1, SKOV-3, Ovar-4, Ovar-5 and Ovar-8 | Induce apoptosis; both activate and block the autophagy. Lipophilic statins were more potent than hydrophilic statins. | Rab7/p62/LC3-II. | [87]       |
| simvastatin              | in vitro and in vivo              | SKOV3, OVCAR3, and ID8 | Induce apoptosis and inhibit tumor growth. |                      | [88]       |
| simvastatin              | in vitro and in vivo              | Hey, SKOV3, and KpB mice | Anti-metastatic and anti-tumorigenic effects. | MAPK and AKT/mTOR.                 | [89]       |
| Atorvastatin, fluvasatin, simvastatin | in vitro                         | CaSki, HeLa, and ViBo | Induce apoptosis.                         |                      | [90]       |
| simvastatin + paclitaxel | in vitro and in vivo              | SiHa, C33A, HeLa, and ViBo | Induce apoptosis and autophagy and inhibit tumor growth; synergized with paclitaxel. | RAF, ERK1/2, Akt, mTOR, and p53. | [91]       |
| Atorvastatin             | in vitro and in vivo              | SiHa and Caski        | Induce apoptosis and autophagy and inhibit tumor growth. | AMPK, Akt/mTOR.                   | [92]       |

Lovastatin and Pravastatin decreased metastasis through RhoA signaling in vitro and in vivo of SKOV3 ovarian cancer cells [82]. In addition, lovastatin and atorvastatin induced apoptosis in Hey 1B and Ovcar-3 ovarian cancer cells and suppressed anchorage-independent growth of these cells through the JNK/Rac1/Cdc42 pathway [83]. Lovastatin synergizes with doxorubicin to induce apoptosis by a novel mevalonate-independent mechanism [84]. In the mogp-TAg mouse model, the promoter of oviduct glycoprotein-1 was used to drive the expression of SV40 T-antigen, and serous tubal intraepithelial carcinomas (STICs) were developed in gynecologic tissues. Lovastatin significantly reduced the development of STICs in mogp-TAg mice and inhibited ovarian tumor growth in the mouse xenograft model. Furthermore, lovastatin induced autophagy in ovarian cancer cells in vitro [85]. Simvastatin inhibited the proliferation of ovarian clear cell RMG-1 and TOV21-G in vitro and tumor growth in vivo [86]. All statins except pravastatin demonstrated single-agent activity against monolayers (IC50 = 1–35 μM) and spheroids (IC50 = 1–13 μM) of ovarian cancer cells. Furthermore, simvastatin could activate and block autophagy through the Rab7/p62/LC3-II pathway, and the lipophilic statins, simvastatin, and fluvasatin were more potent than hydrophilic statins [87]. In the ID8 syngeneic mice model, simvastatin induced apoptosis and inhibit tumor growth of ovarian cancer [88]. In a K18-gT121+/− p53fl/fl Brca1fl/fl (KpB) mouse model, a unique serous ovarian cancer mouse
model specifically and somatically deletes Brca1 and p53 and inactivates the retinoblastoma (Rb) proteins; simvastatin reduced the orthotropic xenograft tumor. In vitro studies showed that simvastatin obtained anti-metastatic and anti-tumorigenic effects through MAPK and AKT/mTOR pathways [89] (Table 5).

Atorvastatin, fluvastatin, and simvastatin induced apoptosis in cervical cancer cells, CaSki, HeLa, and ViBo (established from a biopsy derived from a cervical tumor) [90]. Moreover, simvastatin reduced the phosphorylation of Raf, ERK1/2, Akt, and mTOR and prenylated Ras, resulting in the induction of apoptosis and inhibition of cervical cancer tumor growth. A combination of simvastatin and paclitaxel abolished tumor growth in vivo [91]. In addition, apoptosis and autophagy were induced by atorvastatin through the AMPK/Akt/mTOR pathway. The xenograft tumor was reduced when treated with atorvastatin [92] (Table 5).

In summary, statins showed great potential to reduce cell proliferation and tumor growth of gynecological cancer in vitro and in vivo. Akt/mTOR is the most important pathway in regulating cell proliferation, and a combination of statins with chemo drugs could synergize the anti-tumorigenic effects. Based on this foundation, statins may be a candidate repurposed drug for gynecological cancers.

10. Conclusions and Perspective

The mevalonate pathway and lipid metabolism are linked to the key regulators, influencing gene expression, chromatin remodeling, cellular differentiation, stress response, and tumor microenvironment that collectively enhance tumor development [93]. Statins obtain pleiotropic roles to decrease tumor progression through mevalonate-dependent and independent pathways. Statins reduced the prenylated small GTPase and other signaling pathways, such as Akt/mTOR, to induce apoptosis and autophagy and inhibit cell proliferation and metastasis, resulting in anti-tumor development.

This review of statin use in gynecological cancers showed positive and negative results. Some studies cannot avoid confounders, including multiple comorbidities, lifestyle factors, health-related behaviors, stage and grade of disease, and other medications. The study or clinical trials of different statins (e.g., lipophilic or hydrophilic) on different histotypes of cancer (e.g., serous type or non-serous type; type I or type II) and in combination with chemo drugs are required to validate since there are only 3 trials on EC, 6 trials on ovarian cancer, compared to breast cancer which has 52 trials.

If statins are to be applied clinically to gynecological cancers, they may be used as a single agent. We advocate that using statins in combination with other drugs is more potent. In addition, the identification of the response prediction markers is just undergoing. In ovarian cancer cells, VDAC1 and LDLRAP1 were positively and negatively correlated with the response to statins, respectively [94].

The value of statins as therapeutic drugs against gynecological cancer is inestimable because the repurposing of inexpensive, commonly used, and FDA-approved medications to exploit their anti-cancer effects yields the development of cost-effective approaches to cancer therapy. Most important, it can directly benefit the patients, life-saving or prolonging.

Author Contributions: Conceptualization, K.-H.W., C.-H.L. and D.-C.D.; methodology, K.-H.W.; formal analysis, K.-H.W.; investigation, K.-H.W.; resources, K.-H.W.; data curation, K.-H.W.; writing—original draft preparation, K.-H.W. and D.-C.D.; writing—review and editing, D.-C.D. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Hualien Tzu Chi Hospital (TCRD 108-57, 108-49, 109-62, TCRD 111-071, TCRD 111-080) and the Buddhist Tzu Chi Medical Foundation (TCMF-EP 111-01, TCMF-CP 111-05).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.
Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Prasad, V.; Mailankody, S. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval. *JAMA Intern. Med.* 2017, 177, 1569–1575. [CrossRef] [PubMed]

2. Matuszewicz, L.; Meissner, J.; Toporkiewicz, M.; Sikorski, A.F. The Effect of Statins on Cancer Cells—Review. *Tumour Biol.* 2015, 36, 4889–4904. [CrossRef] [PubMed]

3. Wang, A.; Aragaki, A.K.; Tang, J.Y.; Kurian, A.W.; Manson, J.E.; Chlebowski, R.T.; Simon, M.; Desai, P.; Wassertheil-Smoller, S.; Liu, S.; et al. Statin Use and All-Cancer Survival: Prospective Results from the Women’s Health Initiative. *Br. J. Cancer* 2016, 115, 129–135. [CrossRef] [PubMed]

4. Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jamal, A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J. Clin.* 2018, 68, 394–424. [CrossRef] [PubMed]

5. Alraijal, A.; Pansare, V.; Choudhury, M.S.R.; Khan, M.Y.A.; Shidham, V.B. Squamous Intraepithelial Lesions (SIL): LSIL, HSIL, ASC-US, ASC-H, LSIL-H) of Uterine Cervix and Bethesda System. *CytPath* 2021, 18, 16. [CrossRef]

6. Bouvard, V.; Baan, R.; Straif, K.; Grosse, Y.; Secretan, B.; El Ghissassi, F.; Benbrahim-Tallaa, L.; Guha, N.; Freeman, C.; Galichet, L.; et al. A Review of Human Carcinogens—Part B: Biological Agents. *Lancet Oncol.* 2009, 10, 321–322. [CrossRef]

7. Clifford, G.M.; de Vuyst, H.; Tenet, V.; Plummer, M.; Tully, S.; Franceschi, S. Effect of HIV Infection on Human Papillomavirus Types Causing Invasive Cervical Cancer in Africa. *J. Acquir. Immune Defic. Syndr.* 2016, 73, 332–339. [CrossRef]

8. GlaxoSmithKline Vaccine HPV-007 Study Group; Romanowski, B.; de Borba, P.C.; Naud, P.S.; Roteli-Martins, C.M.; De Carvalho, N.S.; Teixeira, J.C.; Aoki, F.; Ramjattan, B.; Shier, R.M.; et al. Sustained Efficacy and Immunogenicity of the Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine: Analysis of a Randomised Placebo-Controlled Trial up to 6.4 years. *Lancet* 2009, 374, 1975–1985.

9. Ngan, H.Y.S.; Garland, S.M.; Bhatla, N.; Pagliusi, S.R.; Chan, K.K.L.; Cheung, A.N.Y.; Chu, T.-Y.; Domingo, E.J.; Qiao, Y.L.; Park, J.S.; et al. Asia Oceania Guidelines for the Implementation of Programs for Cervical Cancer Prevention and Control. *J. Cancer Epidemiol.* 2011, 2011, 794861. [CrossRef]

10. Brüggmann, D.; Ouassou, K.; Klingelhöfer, D.; Bohlmann, M.K.; Jaque, J.; Groneberg, D.A. Endometrial Cancer: Mapping the Global Landscape of Research. *J. Transl. Med.* 2020, 18, 386. [CrossRef]

11. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jamal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J. Clin.* 2021, 71, 209–249. [CrossRef] [PubMed]

12. Connor, E.V.; Rose, P.G. Management Strategies for Recurrent Endometrial Cancer. *Expert Rev. Anticancer Ther.* 2018, 18, 873–885. [CrossRef] [PubMed]

13. Soslow, R.A.; Tornos, C.; Park, K.J.; Malpica, A.; Matias-Guiu, X.; Oliva, E.; Parkash, V.; Carlson, J.; McCluggage, W.G.; Gilks, C.B. Endometrial Carcinoma Diagnosis: Use of FIGO Grading and Genomic Subcategories in Clinical Practice: Recommendations of the International Society of Gynecological Pathologists. *Int. J. Gynecol. Pathol.* 2014, 33, 28–36. [CrossRef]

14. Esposito, K.; Chiodini, P.; Capuano, A.; Bellastella, G.; Maiorino, M.I.; Giugliano, D. Metabolic Syndrome and Endometrial Cancer: A Meta-Analysis. *Endocrine* 2014, 45, 28–36. [CrossRef]

15. Rosato, V.; Zucchetto, A.; Bosetti, C.; Dal Maso, L.; Montella, M.; Pelucchi, C.; Negri, E.; Franceschi, S.; La Vecchia, C. Metabolic Syndrome and Endometrial Cancer Risk. *Ann. Oncol.* 2011, 22, 884–889. [CrossRef]

16. Barry, J.A.; Azziza, M.M.; Hardiman, P.J. Risk of Endometrial, Ovarian and Breast Cancer in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. *Hum. Reprod. Update* 2014, 20, 748–758. [CrossRef] [PubMed]

17. Brinton, L.A.; Berman, M.L.; Mortel, R.; Twigg, L.B.; Barrett, R.J.; Wilbanks, G.D.; Lannom, L.; Hoover, R.N. Reproductive, Menstrual, and Medical Risk Factors for Endometrial Cancer: Results from a Case-Control Study. *Am. J. Obstet. Gynecol.* 1992, 167, 1317–1325. [CrossRef]

18. Zucchetto, A.; Serraino, D.; Polesel, J.; Negri, E.; De Paoli, A.; Dal Maso, L.; Montella, M.; La Vecchia, C.; Franceschi, S.; Talamini, R. Hormone-Related Factors and Gynecological Conditions in Relation to Endometrial Cancer Risk. *Eur. J. Cancer Prev.* 2009, 18, 316–321. [CrossRef]

19. Siegel, R.L.; Miller, K.D.; Jamal, A. Cancer Statistics, 2020. *CA Cancer J. Clin.* 2020, 70, 7–30. [CrossRef]

20. Koshiyama, M.; Matsumura, N.; Konishi, I. Recent Concepts of Ovarian Carcinogenesis: Type I and Type II. *Biomed. Res. Int.* 2014, 2014, 934261. [CrossRef]

21. Lee, Y.; Miron, A.; Drapkin, R.; Nucci, M.R.; Medeiros, F.; Saleemuddin, A.; Garber, J.; Birch, C.; Mou, H.; Gordon, R.W.; et al. A Candidate Precursor to Serous Carcinoma That Originates in the Distal Fallopian Tube. *J. Pathol.* 2007, 211, 26–35. [CrossRef] [PubMed]

22. Kim, J.; Coffey, D.M.; Creighton, C.J.; Yu, Z.; Hawkins, S.M.; Matzuk, M.M. High-Grade Serous Ovarian Cancer Arises from Fallopian Tube in a Mouse Model. *Proc. Natl. Acad. Sci. USA* 2012, 109, 3921–3926. [CrossRef] [PubMed]

23. Momenimovahed, Z.; Tiznobaik, A.; Taheri, S.; Salehinia, H. Ovarian Cancer in the World: Epidemiology and Risk Factors. *Int. J. Women’s Health* 2019, 11, 287–299. [CrossRef] [PubMed]
24. Iyoshi, S.; Sumi, A.; Yoshihara, M.; Kitami, K.; Mogi, K.; Uno, K.; Fujimoto, H.; Miyamoto, E.; Tano, S.; Yoshikawa, N.; et al. Obesity Contributes to the Stealth Peritoneal Dissemination of Ovarian Cancer: A Multi-Institutional Retrospective Cohort Study. *Obesity* **2022**, *30*, 1599–1607. [CrossRef]

25. Goldstein, J.L.; Brown, M.S. A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins. *Cell* **2015**, *161*, 161–172. [CrossRef]

26. Oryani, A.; Kamali, A.; Moshiri, A. Potential Mechanisms and Applications of Statins on Osteogenesis: Current Modalities, Conflicts and Future Directions. *J. Control. Release* **2015**, *215*, 12–24. [CrossRef]

27. Endo, A. The Origin of the Statins. *Atheroscler. Suppl.* **2004**, *5*, 125–130. [CrossRef]

28. Schonewille, M.; de Boer, J.E.; Mele, L.; Wolters, H.; Bloks, V.W.; Wolters, J.C.; Kuivenhoven, J.A.; Tietge, U.J.E.; Brufau, G.; Groen, A.K. Statins Increase Hepatic Cholesterol Synthesis and Stimulate Fecal Cholesterol Elimination in Mice. *J. Lipid Res.* **2016**, *57*, 1455–1464. [CrossRef]

29. Abd, T.T.; Jacobson, T.A. Statin-Induced Myopathy: A Review and Update. *Expert Opin. Drug Saf.* **2011**, *10*, 373–387. [CrossRef]

30. Di Bello, E.; Zwerdel, C.; Mai, A.; Valente, S. The Innovative Potential of Statins in Cancer: New Targets for New Therapies. *Front. Chem.* **2020**, *8*, 516. [CrossRef]

31. Campbell, M.J.; Esserman, L.J.; Zhou, Y.; Shoemaker, M.; Lobo, M.; Borman, E.; Baehner, F.; Kumar, A.S.; Adduci, K.; Marx, C.; et al. Breast Cancer Growth Prevention by Statins. *Cancer Res.* **2006**, *66*, 8707–8714. [CrossRef] [PubMed]

32. Wang, S.-T.; Ho, H.J.; Lin, J.-T.; Shieh, J.-J.; Wu, C.-Y. Simvastatin-Induced Cell Cycle Arrest through Inhibition of STAT3/SPK2 Axis and Activation of AMPK to Promote p27 and p21 Accumulation in Hepatocellular Carcinoma Cells. *Cell Death Dis.* **2017**, *8*, e2626. [CrossRef] [PubMed]

33. Yin, L.; He, Z.; Yi, B.; Xue, L.; Sun, J. Simvastatin Suppresses Human Breast Cancer Cell Invasion by Decreasing the Expression of Pituitary Tumor-Transforming Gene 1. *Front. Pharmacol.* **2020**, *11*, 574068. [CrossRef] [PubMed]

34. Zhu, B.; Gong, Y.; Yan, G.; Wang, D.; Wang, Q.; Qiao, Y.; Hou, J.; Liu, B.; Tang, C. Atorvastatin Treatment Modulates p16 Promoter Methylation to Regulate p16 Expression. *FEBS J.* **2017**, *284*, 1868–1881. [CrossRef]

35. Dongoran, R.A.; Wang, K.-H.; Lin, T.-J.; Yuan, T.-C.; Liu, C.-H. Anti-Proliferative Effect of Statins Is Mediated by DNMT1 Inhibition and p21 Expression in OSCC Cells. *Cancers* **2020**, *12*, 2084. [CrossRef]

36. Forero-Peña, D.A.; Gutierrez, F.R.S. Statins as Modulators of Regulatory T-Cell Biology. *Mediat. Inflamm.* **2013**, *2013*, 167086. [CrossRef]

37. Shahbaz, S.K.; Sadeghi, M.; Koushki, K.; Penson, P.E.; Sahebkar, A. Regulatory T Cells: Possible Mediators for the Anti-Inflammatory Action of Statins. *Pharmacol. Res.* **2019**, *149*, 104469. [CrossRef]

38. Ulivieri, C.; Baldari, C.T. Statins: From Cholesterol-Lowering Drugs to Novel Immunomodulators for the Treatment of Th17-Mediated Autoimmune Diseases. *Pharmacol. Res.* **2014**, *88*, 41–52. [CrossRef]

39. Rodriguez-Perea, A.L.; Rojas, M.; Velilla-Hernández, P.A. High Concentrations of Atorvastatin Reduce in-Vitro Function of Conventional T and Regulatory T Cells. *Clin. Exp. Immunol.* **2019**, *196*, 237–248. [CrossRef]

40. Cantini, L.; Pecci, F.; Hurkmans, D.P.; Belderbos, R.A.; Lanese, A.; Copparoni, C.; Aerts, S.; Cornelissen, R.; Dumoulin, D.W.; Fiordiliva, I.; et al. High-Intensity Statins Are Associated with Improved Clinical Activity of PD-1 Inhibitors in Malignant Pleural Mesothelioma and Advanced Non-Small Cell Lung Cancer Patients. *Eur. J. Cancer* **2021**, *144*, 41–48. [CrossRef]

41. Oechsle, C.M.; Showalter, L.E.; Novak, C.M.; Czernecki, B.J.; Koski, G.K. Statin Drugs Plus Th1 Cytokines Potentiate Apoptosis and Ras Delocalization in Human Breast Cancer Lines and Combine with Dendritic Cell-Based Immunotherapy to Suppress Tumor Growth in a Mouse Model of HER-2pos Disease. *Vaccines* **2020**, *8*, 72. [CrossRef] [PubMed]

42. Sarrabayrouse, G.; Pich, C.; Teiti, I.; Tilkin-Mariame, A.F. Regulatory Properties of Statins and Rho GTPases Prenylation Inhibitors to Stimulate Melanoma Immunogenicity and Promote Anti-Melanoma Immune Response. *Int. J. Cancer* **2017**, *140*, 747–755. [CrossRef] [PubMed]

43. Gorabi, A.M.; Kiaie, N.; Pirro, M.; Bianconi, V.; Jamalahmadi, T.; Sahebkar, A. Effects of Statins on the Biological Features of Mesenchymal Stem Cells and Therapeutic Implications. *Heart Fail. Rev.* **2021**, *26*, 1259–1272. [CrossRef]

44. Galland, S.; Martin, P.; Fregni, G.; Letovance, I.; Stamenkovic, I. Attenuation of the pro-Inflammatory Signature of Lung Cancer-Derived Mesenchymal Stromal Cells by Statins. *Cancer Lett.* **2020**, *484*, 50–64. [CrossRef]

45. Chen, Y.; Han, L.; Zheng, A. Association between Statin Use and the Risk, Prognosis of Gynecologic Cancer: A Meta-Analysis. *Eur. J. Obstet. Gynecol. Reprod. Biol.* **2022**, *268*, 74–81. [CrossRef]

46. Li, J.; Liu, R.; Sun, Z.; Tang, S.; Wang, L.; Liu, C.; Zhao, W.; Yao, Y.; Sun, C. The Association between Statin Use and Endometrial Cancer Survival Outcome: A Meta-Analysis. *Medicine* **2018**, *97*, e13264. [CrossRef]

47. Wang, Y.; Ren, F.; Song, Z.; Chen, P.; Liu, S.; Ouyang, L. Statin Use and the Risk of Ovarian and Endometrial Cancers: A Meta-Analysis. *BMC Cancer* **2019**, *19*, 730. [CrossRef]

48. Yang, J.; Zhu, Q.; Liu, Q.; Wang, Y.; Xie, W.; Hu, L. Statin Use and Endometrial Cancer Risk: A Meta-Analysis. *Oncotarget* **2017**, *8*, 62425–62434. [CrossRef]

49. Yu, O.; Boudreau, D.M.; Buist, D.S.M.; Miglioretti, D.L. Statin Use and Female Reproductive Organ Cancer Risk in a Large Population-Based Setting. *Cancer Causes Control* **2009**, *20*, 609–616. [CrossRef]

50. Yoon, L.S.; Goodman, M.T.; Rimel, B.J.; Jeon, C.Y. Statin Use and Survival in Elderly Patients with Endometrial Cancer. *Gynecol. Oncol.* **2015**, *137*, 252–257. [CrossRef]
76. Hanley, G.E.; Kaur, P.; Berchuck, A.; Chase, A.; Grout, B.; Deurloo, C.M.; Pike, M.; Richardson, J.; Terry, K.L.; Webb, P.M.; et al. Cardiovascular Medications and Survival in People with Ovarian Cancer: A Population-Based Cohort Study from British Columbia, Canada. Gynecol. Oncol. 2021, 162, 461–468. [CrossRef] [PubMed]

77. Kim, D.-S.; Ahn, H.S.; Kim, H.J. Statin Use and Incidence and Mortality of Breast and Gynecologic Cancer: A Cohort Study Using the National Health Insurance Claims Database. Int. J. Cancer 2022, 150, 1156–1165. [CrossRef] [PubMed]

78. Song, M.-K.; Shin, B.-S.; Ha, C.-S.; Park, W.-Y. Would Lipophilic Statin Therapy as a Prognostic Factor Improve Survival in Patients With Uterine Cervical Cancer? Int. J. Gynecol. Cancer 2017, 27, 1431–1437. [CrossRef]

79. Schointuch, M.N.; Gilliam, T.P.; Stine, J.E.; Han, X.; Zhou, C.; Gehrig, P.A.; Kim, K.; Bae-Jump, V.L. Simvastatin, an HMG-CoA Reductase Inhibitor, Exhibits Anti-Metastatic and Anti-Tumorigenic Effects in Endometrial Cancer. Gynecol. Oncol. 2014, 134, 346–355. [CrossRef]

80. Kim, J.S.; Turbové, J.; Rosales, R.; Thaete, L.G.; Rodriguez, G.C. Combination Simvastatin and Metformin Synergistically Inhibits Endometrial Cancer Cell Growth. Gynecol. Oncol. 2019, 154, 432–440. [CrossRef]

81. Kato, S.; Smalley, S.; Sadarangani, A.; Chen-Lin, K.; Oliva, B.; Brafes, J.; Carvajal, J.; Gejman, R.; Owen, G.I.; Cuello, M. Lipophilic but Not Hydrophilic Statins Selectively Induce Cell Death in Gynaecological Cancers Expressing High Levels of HMGCoA Reductase. J. Cell. Mol. Med. 2010, 14, 1180–1193. [PubMed]

82. Horiuchi, A.; Kikuchi, N.; Osada, R.; Wang, C.; Hayashi, A.; Nikaido, T.; Konishi, I. Overexpression of RhoA Enhances Peritoneal Dissemination: RhoA Suppression with Lovastatin May Be Useful for Ovarian Cancer. Cancer Sci. 2008, 99, 2532–2539. [CrossRef] [PubMed]

83. Liu, H.; Liang, S.-L.; Kumar, S.; Weyman, C.M.; Liu, W.; Zhou, A. Statins Induce Apoptosis in Ovarian Cancer Cells through Activation of JNK and Enhancement of Bim Expression. Cancer Chemother. Pharmacol. 2009, 63, 997–1005. [CrossRef] [PubMed]

84. Martirosyan, A.; Clendening, J.W.; Goard, C.A.; Penn, L.Z. Lovastatin Induces Apoptosis of Ovarian Cancer Cells and Synergizes with Doxorubicin: Potential Therapeutic Relevance. BMC Cancer 2010, 10, 103. [CrossRef] [PubMed]

85. Kobayashi, Y.; Kashima, H.; Wu, R.-C.; Jung, J.-G.; Kuan, J.-C.; Gu, J.; Xuan, J.; Sokoll, L.; Visvanathan, K.; Shih, I.-M.; et al. Mevalonate Pathway Antagonist Suppresses Formation of Serous Tubal Intraepithelial Carcinoma and Ovarian Carcinoma in Mouse Models. Clin. Cancer Res. 2015, 21, 4652–4662. [CrossRef]

86. Matsuura, M.; Suzuki, T.; Suzuki, M.; Tanaka, R.; Ito, E.; Saito, T. Statin-Mediated Reduction of Osteopontin Expression Induces Apoptosis and Cell Growth Arrest in Ovarian Clear Cell Carcinoma. Oncol. Rep. 2011, 25, 41–47. [CrossRef]

87. Robinson, E.; Nandi, M.; Wilkinson, L.L.; Arrowsmith, D.M.; Curtis, A.D.M.; Richardson, A. Preclinical Evaluation of Statins as a Treatment for Ovarian Cancer. Gynecol. Oncol. 2013, 129, 417–424. [CrossRef]

88. Greenaway, J.B.; Virtanen, C.; Osz, K.; Revay, T.; Hardy, D.; Shepherd, T.; DiMattia, G.; Petrik, J. Ovarian Tumour Growth Is Characterized by Mevalonate Pathway Gene Signature in an Orthotopic, Syngeneic Model of Epithelial Ovarian Cancer. Oncotarget 2016, 7, 47343–47365. [CrossRef]

89. Stine, J.E.; Goo, H.; Sheng, X.; Han, X.; Schointuch, M.N.; Gilliam, T.P.; Gehrig, P.A.; Zhou, C.; Bae-Jump, V.L. The HMG-CoA Reductase Inhibitor, Simvastatin, Exhibits Anti-Metastatic and Anti-Tumorigenic Effects in Ovarian Cancer. Oncotarget 2016, 7, 946–960. [CrossRef]

90. Crescencio, M.E.; Rodriguez, E.; Páez, A.; Masso, F.A.; Montaño, L.F.; López-Marure, R. Statins Inhibit the Proliferation and Induce Cell Death of Human Papilloma Virus Positive and Negative Cervical Cancer Cells. Int. J. Biomed. Sci. 2009, 5, 411–420. [CrossRef]

91. Pan, Q.; Xu, J.; Ma, L. Simvastatin Enhances Chemotherapy in Cervical Cancer via Inhibition of Multiple Prenylation-Dependent GTPases-Regulated Pathways. Fundam. Clin. Pharmacol. 2020, 34, 32–40. [CrossRef] [PubMed]

92. Sheng, B.; Song, Y.; Zhang, J.; Li, R.; Wang, Z.; Zhu, X. Atorvastatin Suppresses the Progression of Cervical Cancer via Regulation of Autophagy. Am. J. Transl. Res. 2020, 12, 5252–5268. [PubMed]

93. Li, Z.; Kang, Y. Lipid Metabolism Fuels Cancer’s Spread. Cell Metab. 2017, 25, 228–230. [CrossRef] [PubMed]

94. Kobayashi, Y.; Takeda, T.; Kunitomi, H.; Chiwaki, F.; Komatsu, M.; Nagai, S.; Nogami, Y.; Tsuji, K.; Masuda, K.; Ogiwara, H.; et al. Response Predictive Markers and Synergistic Agents for Drug Repositioning of Statins in Ovarian Cancer. Pharmaceuticals 2022, 15, 124. [CrossRef] [PubMed]